Fallopian tube origin of supposed ovarian high-grade serous carcinomas

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author DINIZ, Patricia Martini FMUSP-HC
CARVALHO, Jesus Paula FMUSP-HC
BARACAT, Edmund Chada FMUSP-HC
CARVALHO, Filomena M. FMUSP-HC
dc.date.issued 2011
dc.identifier.citation CLINICS, v.66, n.1, p.73-76, 2011
dc.identifier.issn 1807-5932
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/23223
dc.description.abstract INTRODUCTION: Serous carcinomas are the most frequent histologic type of ovarian and peritoneal cancers, and can also be detected in the endometrium and fallopian tubes. Serous carcinomas are usually high-grade neoplasms when diagnosed, yet the identification of an associated precursor lesion remains challenging. Pathological examination of specimens obtained from prophylactic bilateral salpingo-oophorectomies that were performed for patients harboring BRCA1/2 mutations suggests that high-grade serous carcinomas may arise in the fallopian tubes rather than in the ovaries. OBJECTIVE: To investigate the presence and extent of fallopian tube involvement in cases of serous pelvic carcinomas. METHODS: Thirty-four cases of serous pelvic carcinoma with clinical presentations suggesting an ovarian origin were analyzed retrospectively. Histologic samples of fallopian tube tissues were available for these cases and were analyzed. Probable primary site, type of tubal involvement, tissues involved in the neoplasia and vascular involvement were evaluated. RESULTS: Fallopian tube involvement was observed in 24/34 (70.6%) cases. In 4 (11.8%) of these cases, an intraepithelial neoplasia was present, and therefore these cases were hypothesized to be primary from fallopian tubes. For an additional 7/34 (20.6%) cases, a fallopian tube origin was considered a possible primary. CONCLUSIONS: Fallopian tubes can be the primary site for a subset of pelvic high-grade serous carcinomas.
dc.language.iso eng
dc.publisher HOSPITAL CLINICAS, UNIV SAO PAULO
dc.relation.ispartof Clinics
dc.rights openAccess
dc.subject Serous carcinoma; Ovarian cancer; Fallopian tube carcinoma; Peritoneal cancer; BRCA1; BRCA2
dc.subject.other intraepithelial carcinoma; new-model; cancer; mutations; carcinogenesis; pathogenesis; fimbria; tumors; kras; braf
dc.title Fallopian tube origin of supposed ovarian high-grade serous carcinomas
dc.type article
dc.rights.holder Copyright HOSPITAL CLINICAS, UNIV SAO PAULO
dc.description.group LIM/14
dc.description.group LIM/58
dc.identifier.doi 10.1590/S1807-59322011000100013
dc.identifier.pmid 21437439
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author DINIZ, Patricia Martini:FM:
hcfmusp.author CARVALHO, Jesus Paula:FM:MOG
hcfmusp.author BARACAT, Edmund Chada:FM:MOG
hcfmusp.author CARVALHO, Filomena M.:FM:MPT
hcfmusp.origem.id WOS:000288712700013
hcfmusp.origem.id 2-s2.0-79952926778
hcfmusp.publisher.city SAO PAULO
hcfmusp.publisher.country BRAZIL
hcfmusp.relation.reference · Winter WE, 2008, J CLIN ONCOL, V26, P83, DOI 10.1200/JCO.2007.13.1953
· Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521
· Seidman JD, 2004, INT J GYNECOL PATHOL, V23, P41, DOI 10.1097/01.pgp.0000101080.35393.16
· Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d
· Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47
· Salvador S, 2009, INT J GYNECOL CANCER, V19, P58, DOI 10.1111/IGC.0b013e318199009c
· Gershenson DM, 2006, OBSTET GYNECOL, V108, P361, DOI 10.1097/01.AOG.0000227787.24587.d1
· Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
· Singer G, 2002, AM J PATHOL, V160, P1223, DOI 10.1016/S0002-9440(10)62549-7
· Carlson JW, 2008, J CLIN ONCOL, V26, P4160, DOI 10.1200/JCO.2008.16.4814
· Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77
· Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa
· Mehrad M, 2010, ADV ANAT PATHOL, V17, P293, DOI 10.1097/PAP.0b013e3181ecdee1
· Folkins AK, 2009, GYNECOL ONCOL, V113, P391, DOI 10.1016/j.ygyno.2009.01.013
· Singer G, 2003, J NATL CANCER I, V95, P484
· Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091
· Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79
· Crum CP, 2007, CURR OPIN OBSTET GYN, V19, P3, DOI 10.1097/GCO.0b013e328011a21f
· Carvalho JP, 2008, MED HYPOTHESES, V71, P690, DOI 10.1016/j.mehy.2008.06.028
· Crum CP, 2010, CANCER-AM CANCER SOC, V116, P5119, DOI 10.1002/cncr.25450
· Crum Christopher P, 2007, Clin Med Res, V5, P35, DOI 10.3121/cmr.2007.702
· Gadducci A, 2010, GYNECOL ENDOCRINOL, V26, P568, DOI 10.3109/09513590.2010.487609
· Sogaard M, 2006, ACTA OBSTET GYN SCAN, V85, P93, DOI 10.1080/00016340500324621
· Nikrui N, 1998, Surg Oncol Clin N Am, V7, P363
· Shih le M., 2004, AM J PATHOL, V164, P1511
dc.description.index MEDLINE
hcfmusp.citation.scopus 17
hcfmusp.scopus.lastupdate 2021-08-27


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics